Professional Statements and Societal Positions Guidelines
National Institute For Health And Care Excellence-2019
In June 2019, the National Institute For Health And Care Excellence published interventional procedures guidance [IPG653] regarding valve-in-valve TAVI for aortic bioprosthetic valve dysfunction. The guidance was informed by an Interventional procedure overview described previously. The guidance recommendation is that "Current evidence on the safety and efficacy of valve-in-valve transcatheter aortic valve implantation (ViV‑TAVI) for aortic bioprosthetic dysfunction is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit."
The American College of Cardiology and the American Heart Association – 2017
The American College of Cardiology and the American Heart Association in the 2017 guidelines on the management of valvular heart disease provider recommendations in 2 categories for Mitral Valve repair.
Primary Mitral Valve disease: Transcatheter mitral valve repair may be considered for severely symptomatic individuals (New York Heart Association (NYHA) class III to IV with chronic severe primary mitral regurgitation who have favorable anatomy for the repair procedure and a reasonable life expectancy but who have a prohibitive surgical risk because of severe comorbidities and remain severely symptomatic despite optimal guideline directed medical therapy for heart failure.
Secondary Mitral Regurgitation: Mitral valve surgery is reasonable for individuals with chronic severe secondary mitral regurgitation who are undergoing Coronary Artery Bypass Graft or Atrial Valve Repair. Also Mitral valve repair or replacement may be considered for severely symptomatic individuals (NYHA class III to IV) with chronic severe mitral regurgitation who have persistent symptoms despite optimal guideline directed medical therapy for heart failure.
